The Clinical Evaluation Report (CER) serves as a foundational technical document that summarizes the evaluation of information pertaining to the clinical use of a medical device. It is not a static document but rather a detailed summary that synthesizes a vast array of data to determine whether a medical device possesses an acceptable benefit-risk ratio for its specific intended purpose. The CER is a regulatory necessity, mandated under Regulation (EU) 2017/745 (MDR), specifically Article 61 and ANNEX XIV, which dictates that the evaluation of clinical performance, safety, and clinical benefit must be based on clinical data for all medical device classes.
The primary objective of the CER is to provide a thorough understanding of the safety and performance of a device. This is achieved through the identification, collection, appraisal, and analysis of both pre-market and post-market clinical data. This rigorous process is designed to demonstrate compliance with the General Safety and Performance Requirements (GSPR) as outlined by the MDR. By integrating preclinical, non-clinical, and clinical data from diverse sources, the CER establishes a methodologically rigorous ongoing process that ensures a device is safe for its intended use and performs as claimed.
The creation of a CER is a complex undertaking that requires the integration of various strategic plans. This includes the Clinical Evaluation Plan (CEP), which defines the scope, target populations, and medical indications, and the Clinical Development Plan (CDP). The CDP specifically maps the progression from exploratory investigations—such as first-in-man studies, pilot studies, and feasibility trials—to confirmatory investigations, including pivotal clinical investigations and Post-Market Clinical Follow-up (PMCF) plans. Together, these elements ensure that the CER is not merely a snapshot of data but a comprehensive analysis of the device's life cycle.
Strategic Planning and Scope Definition
The initial phase of producing a Clinical Evaluation Report is the establishment of a Clinical Evaluation Plan (CEP). This plan is critical because it sets the boundaries and the methodology for the entire evaluation. Without a predefined plan, the resulting CER would lack the methodological rigor required by regulatory bodies. The CEP describes the specific devices that will be the subject of the CER, ensuring that no component or variation is overlooked.
The scope of the clinical evaluation is extensive and must include a variety of identifiers and historical data. This ensures that the evaluation is grounded in the actual physical and commercial reality of the device.
- Identification of devices covered by the report
- Specific product models and sizes
- Software versions and associated accessories
- Market status, including whether the device is currently on the market
- The date since which the device has been available in specific regions
- Complete history of the device
- Dates of past modifications, including detailed reasons and descriptions for those changes
- Total sales volumes
- Any changes implemented since the last report was issued
The identification of target patient populations and medical indications is also a core component of the planning phase. By defining these parameters, the manufacturer can establish clear clinical benefits to patients, which subsequently forms the basis for the benefit-risk analysis. This planning phase also involves the definition of safety and performance objectives, which are the benchmarks against which the device's actual performance will be measured.
Product Information and Technical Specifications
A comprehensive CER must provide an exhaustive description of the device under evaluation. This section ensures that any reviewer or regulatory body understands exactly what the device is, how it is constructed, and how it functions. This technical transparency is essential for the subsequent appraisal of clinical data.
The product information section typically includes the following administrative and technical details:
- Manufacturer identity
- Product name and specific models
- CE marking status
- Device classification
Beyond basic identification, the CER must delve into the operational and physical nature of the device. This includes the intended use, the target patient population, and the intended medical indication. Furthermore, the report must explicitly address contraindications. If no specific situations exist that would contraindicate the use of the device, the report must state: "There are no known specific situations that contraindicate the use of this device."
The operating principle section requires a detailed overview of the device's architecture. This encompasses:
- Hardware components, software versions, and accessories
- Categorization of the device (for example, a biological artificial aortic valve)
- Physical and chemical attributes
- Technical specifications and mechanical traits
- Sterilization methods utilized
- Radioactivity considerations
- General operational principles
Clinical Data Collection and Literature Review
The cornerstone of a compliant Clinical Evaluation Report is the systematic and methodical literature review. This process is designed to identify all relevant published literature pertaining to the device and the specific claims made about it. The literature review is not a casual search but a structured process consisting of two distinct phases: the literature search and the evaluation of the available literature.
To ensure completeness, this process may be documented in a separate Literature Review Report (LITR). The goal is to yield a sufficient number of relevant publications that meet satisfactory quality standards. This evidence is then used to underscore the safety and performance of the device and to support the intended purpose and clinical benefits as outlined in the manufacturer's informational materials.
The collection of data is an ongoing process that spans the entire life cycle of the device. This includes both pre-market data, collected during the development and trial phases, and post-market data, collected after the device has been released to the general population.
- Pre-market clinical data: Data derived from clinical investigations, feasibility studies, and pivotal trials.
- Post-market clinical data: Data derived from Post-Market Clinical Follow-up (PMCF) and real-world usage.
- Non-clinical testing data: Certain non-clinical data that may affect the benefit-risk analysis are also considered.
Clinical Evidence and Performance Metrics
When compiling clinical evidence, especially for Medical Device Software (MDSW), the CER must focus on three key components. These components ensure that the device's output is not only technically correct but clinically relevant.
The first component is Valid Clinical Association. This involves demonstrating that the device's output (such as calculations, concepts, or conclusions) is associated with the targeted physiological state or clinical condition. This association must be well-founded or clinically accepted. It demonstrates that the device corresponds to the clinical situation, condition, indication, or parameter defined in the intended purpose of the MDSW.
The second component is Technical Performance. This is the demonstration of the device's ability to accurately, reliably, and precisely generate the intended output from the input data. While technical performance is a requirement, it is not sufficient on its own; the output must also be clinically useful.
The third component is Clinical Performance. This involves the demonstration of the device's ability to yield clinically relevant output in accordance with the intended purpose. This means that the technical accuracy translates into a meaningful clinical result for the patient.
| Evidence Component | Focus Area | Requirement |
|---|---|---|
| Valid Clinical Association | Physiological/Clinical State | Association must be well-founded or clinically accepted |
| Technical Performance | Output Generation | Must be accurate, reliable, and precise |
| Clinical Performance | Clinical Relevance | Must yield output relevant to the intended purpose |
Benefit-Risk Assessment and Conclusions
The culmination of the CER is the Benefit-Risk Assessment. This section provides an overview of the risks and benefits associated with the medical device and arrives at a final conclusion regarding the acceptability of the benefit-risk ratio. The objective is to prove that the probable benefits of the device outweigh the potential risks.
The assessment draws upon findings from the clinical data review and the risk analysis. An example of this evaluative logic is as follows: Based on the findings in the clinical data review as well as in the risk analysis, it can be inferred that the probability of a patient experiencing a substantial benefit when using the device outweighs the probability of suffering harm due to a residual risk of the device significantly.
The final section of the CER is the Summary and Conclusion, which often includes an Executive Summary. This summary synthesizes the preclinical, non-clinical, and clinical data from diverse sources. It confirms that the clinical evaluation represents a methodologically rigorous ongoing process. This section marks the point in the life cycle of a device where all data are compiled, and the acceptance criteria for safety and performance objectives are established.
For specific high-risk devices, such as Class III devices and IIb Implantables, a Summary of Safety and Clinical Performance (SSCP) is also required. This ensures that the most critical safety information is distilled for the relevant stakeholders.
Implementation and Maintenance
The preparation and maintenance of a CER is a critical responsibility for medical device companies. While the process may appear to be a cumbersome regulatory activity, the ultimate goal is the advancement of patient safety. Because the contents of a CER vary according to the nature and regulatory history of the medical device, a universal template is often difficult to implement. Instead, companies must adapt their structures to the specific needs of the device.
The CER must be documented with a specified time schedule to ensure it remains current. This includes detailing the search criteria adopted, the available data, all assumptions made, and all conclusions reached. The integration of professional medical writers is often necessary, as they possess the skills and knowledge to ensure that the safety and efficacy of life-saving products are clearly documented and peer-reviewed.